Prospects for the use of new prokinetic with double mechanism of action in the therapy of gasroesophageal reflux disease
The problems of gastroesophageal reflux disease (GERD) and the tactics of treatment with the main pathogenetic mechanisms are discussed. Currently leading trend in the treatment of GERD is acid supression therapy, in particular the proton pump inhibitors (PPI) use. However, given that even the most effective PPI does not affect the underlying cause of illness - motor function disorder of the digestive tract, the use of drugs with prokinetic effect on upper gastrointestinal tract in the treatment of patients with GERD is approved. Itopride hydrochloride (Ganaton) - antagonist of dopamine receptors and blocker of acetylcholinesterase is prokinetic of new generation. Pharmacodynamic and pharmacokinetic characteristics of Ganaton allow using it in patients with GERD in the mode of long-lasting anti-relapse treatment both in combination with PPI and monotherapy.

Keywords: proton pump inhibitors, itopride hydrochloride, prokinetics, duodeno-gastral reflux, lower esophageal sphincter, gastroesophageal reflux disease